Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.72
-0.09 (-1.64%)
Apr 29, 2026, 11:41 AM EDT - Market open
Lexeo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Cash & Equivalents | 63 | 35.01 | 121.47 | 77.34 | 135.86 | Upgrade
|
| Short-Term Investments | 118.77 | 86.5 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 181.77 | 121.52 | 121.47 | 77.34 | 135.86 | Upgrade
|
| Cash Growth | 49.58% | 0.04% | 57.06% | -43.08% | 362.53% | Upgrade
|
| Prepaid Expenses | 6.63 | 4.6 | 2.83 | 2.34 | 0.13 | Upgrade
|
| Other Current Assets | - | - | - | 0.37 | 0.7 | Upgrade
|
| Total Current Assets | 188.39 | 126.12 | 124.29 | 80.05 | 136.68 | Upgrade
|
| Property, Plant & Equipment | 8.86 | 10.56 | 12.26 | 13.78 | 0.17 | Upgrade
|
| Long-Term Investments | 68.19 | 7.01 | - | - | - | Upgrade
|
| Other Long-Term Assets | 3.25 | 3.25 | 3.25 | 3.25 | 0 | Upgrade
|
| Total Assets | 268.69 | 146.94 | 139.81 | 97.08 | 136.86 | Upgrade
|
| Accounts Payable | 4.86 | 6.42 | 3.79 | 2.68 | 3.06 | Upgrade
|
| Accrued Expenses | 9.2 | 13.21 | 10.29 | 8.09 | 3.78 | Upgrade
|
| Current Portion of Leases | 2.68 | 2.67 | 2.61 | 2.83 | - | Upgrade
|
| Current Income Taxes Payable | - | - | - | 0.51 | 0.53 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 0.05 | Upgrade
|
| Other Current Liabilities | 0.07 | 0.55 | 0.55 | 0.24 | 0.03 | Upgrade
|
| Total Current Liabilities | 16.81 | 22.85 | 17.24 | 14.35 | 7.45 | Upgrade
|
| Long-Term Leases | 5.21 | 7.25 | 9.03 | 10.65 | - | Upgrade
|
| Total Liabilities | 22.02 | 30.1 | 26.27 | 25 | 7.45 | Upgrade
|
| Common Stock | 0.01 | 0 | 0 | - | 0 | Upgrade
|
| Additional Paid-In Capital | 626.63 | 397.13 | 295.37 | 2.49 | 0.57 | Upgrade
|
| Retained Earnings | -380.13 | -280.17 | -181.84 | -115.45 | -56.17 | Upgrade
|
| Treasury Stock | -0.02 | -0.02 | - | - | - | Upgrade
|
| Comprehensive Income & Other | 0.19 | -0.1 | - | - | - | Upgrade
|
| Total Common Equity | 246.67 | 116.84 | 113.54 | -112.95 | -55.6 | Upgrade
|
| Shareholders' Equity | 246.67 | 116.84 | 113.54 | 72.08 | 129.41 | Upgrade
|
| Total Liabilities & Equity | 268.69 | 146.94 | 139.81 | 97.08 | 136.86 | Upgrade
|
| Total Debt | 7.89 | 9.92 | 11.64 | 13.48 | - | Upgrade
|
| Net Cash (Debt) | 173.88 | 111.59 | 109.83 | 63.85 | 135.86 | Upgrade
|
| Net Cash Growth | 55.82% | 1.61% | 72.00% | -53.00% | 362.53% | Upgrade
|
| Net Cash Per Share | 3.24 | 3.51 | 20.51 | 39.17 | 87.50 | Upgrade
|
| Filing Date Shares Outstanding | 74.09 | 33.2 | 26.65 | 1.61 | 1.58 | Upgrade
|
| Total Common Shares Outstanding | 73 | 33.07 | 26.65 | 1.61 | 1.58 | Upgrade
|
| Working Capital | 171.58 | 103.28 | 107.06 | 65.7 | 129.24 | Upgrade
|
| Book Value Per Share | 3.38 | 3.53 | 4.26 | -70.28 | -35.18 | Upgrade
|
| Tangible Book Value | 246.67 | 116.84 | 113.54 | -112.95 | -55.6 | Upgrade
|
| Tangible Book Value Per Share | 3.38 | 3.53 | 4.26 | -70.28 | -35.18 | Upgrade
|
| Machinery | 1.61 | 1.23 | 0.89 | 0.65 | 0.19 | Upgrade
|
| Leasehold Improvements | 0.27 | 0.27 | 0.25 | 0.23 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.